Smoking Increases Risk of Side Effects, Recurrence in Prostate Cancer
the Cancer Therapy Advisor take:
Smoking increases risks for side effects and recurrence in patients being treated for prostate cancer, according to a study published in BJU International.
Michael Zelefsky, MD, and colleagues at the Memorial Sloan Kettering Cancer Center in New York City examined 2,358 patients with prostate cancer who underwent external-beam radiotherapy (EBRT) between 1988 and 2005. They classified patients as never smokers, current smokers, former smokers, or current smoking unknown.
They found that with a median follow-up of about 8 years, current smokers were at a 40 percent increased risk of prostate cancer relapse, along with a two-times increased risk of cancer spread and cancer-related death, compared to never smokers.
Additionally, current and former smokers had a higher likelihood of experiencing side effects such as urinary toxicity that are related to radiotherapy.
“Our findings point to the importance of physicians counseling their patients regarding the potential harms of smoking interfering with the efficacy of therapies ad for increased risks of side effects,” Dr. Zelefsky noted.
Smoking increases risks for side effects and recurrence in patients being treated for prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy